Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01054079
Other study ID # IRB00009741
Secondary ID NCI-2009-01514CC
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2011
Est. completion date August 2014

Study information

Verified date July 2018
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment


Description:

PRIMARY OBJECTIVES:

I. To test the hypothesis that once-daily treatment with 30 mg of cinacalcet hydrochloride (Sensipar) will reduce the rate of rise of serum prostate-specific antigen (PSA) compared to pre-treatment PSA values in subjects with biochemically recurrent prostate cancer after failed definitive local therapy.

OUTLINE:

Patients receive cinacalcet hydrochloride orally (PO) once daily (QD) for 20 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate

- For patients who have recurrent disease following surgery as first line therapy ("surgical failures")

- PSA requirement is 0.2 ng/ml or above

- For patients who have recurrent disease following radiation as first line therapy, the eligibility follows the "Phoenix criteria", that is, a rise of 2 ng/mL over the PSA nadir

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Granulocytes >= 1000/uL

- Serum creatinine =< 2.0 mg/dl

- Total serum calcium > 9.0 and < 10.5 mg/dl

- Total bilirubin =< 2.0 mg/dl

- Platelet count >=100,000/uL

- Hemoglobin (Hgb) >= 9 g/dL

- Total testosterone >= 50 ng/dL

- Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)

Exclusion Criteria:

- Serious medical illness which would limit survival to less than 3 months

- Active, uncontrolled bacterial, viral or fungal infection

- Hemorrhagic disorder

- Any radiographic evidence of metastatic disease including positive bone scan or computed tomography (CT) abdomen/pelvis

- History of hypocalcemia or seizure disorder

- Patients with known hypersensitivity to any of the components of cinacalcet (cinacalcet hydrochloride)

Study Design


Intervention

Other:
laboratory biomarker analysis
Correlative study
Procedure:
quality-of-life assessment
Ancillary study
Other:
questionnaire administration
Ancillary study
Drug:
cinacalcet hydrochloride
Given PO

Locations

Country Name City State
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Rise of Serum PSA The difference of post treatment and pre-enrollment PSA.For those with multiple PSA measures post we use the median of those measures to estimate the participant's post PSA level. 24 weeks
Secondary Change in Quality of Life (QOL) as Assessed by the Brief Male Sexual Inventory The Brief Male Sexual Inventory is an 11 question assessment including subscales: sex drive, erections, ejaculation. The scores are totaled to produce an overall score with a range of 1-45, with higher score indicating worse outcomes. Up to 20 weeks
Secondary Change in Hormonal Assessment Scale From Expanded Prostate Cancer Index Composite (EPIC) The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Epic produces two scores, one for function (5 items) and the other for bother (6 items). The response for each item is standardized to a 0 to 100 scale. For both scales, higher scores indicate worse outcomes. up to 20 weeks
Secondary Change in Functional Assessment of Cancer Therapy-Prostate (FACT-P) The FACT-P is a multidimensional, self-report QoL instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain, as well as a global QoL score. All subscale items are summed to a total. The score range is 0-156. Higher scores represent better quality of life. up to 20 weeks
Secondary Change in Total and Free Testosterone The detectable difference is estimated using a paired t-test approach. The lab measure will also be analyzed longitudinally using all measures with a mixed model approach adjusting for individual covariates. Up to 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT02217709 - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Phase 2
Completed NCT03077659 - Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer Phase 2
Active, not recruiting NCT03624660 - Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer N/A
Terminated NCT00512668 - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer Phase 1
Completed NCT00087139 - Ixabepilone in Treating Patients With Metastatic Prostate Cancer Phase 2
Completed NCT00182052 - Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer Phase 3
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Active, not recruiting NCT01655836 - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Phase 1
Terminated NCT03535675 - Muscadine Plus (MPX) In Men With Prostate Cancer Phase 3
Terminated NCT01866423 - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Completed NCT02234921 - Pilot Study of DRibble Vaccine for Prostate Cancer Patients Phase 1
Completed NCT01468532 - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT03686683 - Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Phase 3
Active, not recruiting NCT03689699 - Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Phase 1/Phase 2
Recruiting NCT04694924 - Prospective Prostate Cancer and Patient-reported Outcomes Registry
Active, not recruiting NCT04909294 - Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma N/A
Completed NCT02225925 - Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound N/A
Completed NCT01949519 - Docetaxel and Lycopene in Metastatic Prostate Cancer Phase 1
Completed NCT01433913 - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Phase 2
Completed NCT01228084 - Sulforaphane in Treating Patients With Recurrent Prostate Cancer Phase 2